Home/ Stocks/ CADL

Candel Therapeutics, Inc. Common Stock

CADL XNAS

$8.35 +0.54 (+6.97%) ▲ 15-min delayed

Open

$7.88

High

$8.36

Low

$7.77

Volume

2.53M

Market Cap

$611.81M

About Candel Therapeutics, Inc. Common Stock

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 55 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-38,182,000	$-0.72
FY 2025	$0	$-38,182,000	$-0.72
Q3 2025	$0	$-11,269,000	$-0.21
Q2 2025	$0	$-4,796,000	$-0.09

Related Market News

No specific coverage for CADL yet. Check out our latest market news or earnings calendar.

Get CADL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Candel Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.